SCHEDULE 13G: Madison Avenue Group Discloses 6.4% Passive Stake in Keros Therapeutics

A group of investment entities and individuals led by Eli Samaha, including Madison Avenue Partners and Madison Avenue International, has disclosed a passive beneficial ownership of 6.4% in Keros Therapeutics, Inc.

Summary

• Madison Avenue Partners, LP, Madison Avenue International LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha (collectively, the 'Reporting Persons') have filed a Schedule 13G.
• The filing indicates that the Reporting Persons collectively beneficially own 2,614,402 shares of Keros Therapeutics, Inc. Common Stock.
• This ownership represents approximately 6.4% of the outstanding Common Stock of Keros Therapeutics, Inc.
• The percentage is calculated based on 40,615,414 shares of Common Stock outstanding as of May 1, 2025, as reported in Keros Therapeutics' Quarterly Report on Form 10-Q filed on May 6, 2025.
• The Reporting Persons disclaim any intent to change or influence the control of Keros Therapeutics, Inc., consistent with a passive investment.
• Eli Samaha is identified as the managing member/manager/member across the various Madison Avenue entities, consolidating the beneficial ownership.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an institutional investor group is generally a positive signal, indicating confidence in the company. However, the document itself provides no operational or financial performance data for Keros Therapeutics, limiting a stronger positive sentiment.

Positives

• A significant institutional investor group, Madison Avenue, has taken a 6.4% stake in Keros Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The investment is passive, indicating that the firm is not seeking to influence management or control the company, which can be viewed positively by current management.

Negatives

• The filing does not provide any specific financial or operational details about Keros Therapeutics, limiting the direct insights into the company's performance.
• The passive nature of the investment means the investor group does not intend to actively engage with or influence the company's strategic direction, which might be a missed opportunity for some shareholders seeking activist engagement.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control, meaning the investor group will not actively push for strategic changes, which could be a risk if the company faces performance issues.

Future Outlook

The document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Keros Therapeutics, Inc. or the Reporting Persons regarding the company's future performance or strategic direction.

Management Comments

• The filing includes a certification by Eli Samaha on behalf of the Reporting Persons stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant investment in Keros Therapeutics, Inc., a biotechnology company. Such filings are common in the biotech sector where institutional investors often take positions in companies with promising drug pipelines or technologies. The passive nature of this investment suggests a belief in the company's existing strategy rather than a desire for immediate operational changes, which is typical for long-term investors in growth-oriented industries like biotech.

Comparison to Industry Standards

• This filing is a standard disclosure for an investor group crossing the 5% ownership threshold in a publicly traded company, consistent with SEC regulations.
• The 6.4% stake is a notable position for an institutional investor in a biotechnology company, though without specific financial performance data from Keros Therapeutics, it is not possible to compare its results to industry benchmarks or specific comparable companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals.
• The investment itself, however, signals a vote of confidence from the Madison Avenue group, which is a common occurrence when investment firms identify promising assets within the biotech space.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from this investor group.

Next Steps

• The document does not specify any future actions or milestones for Keros Therapeutics, Inc. or the Reporting Persons, beyond the ongoing passive ownership.

Key Dates

Keywords

Keros Therapeutics, Madison Avenue Partners, Madison Avenue International, Eli Samaha, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Investment, Passive Stake, SEC Filing